ryvyco

Ryvyco is a brand name for the active pharmaceutical ingredient (API) rivaroxaban, which is a direct oral anticoagulant (DOAC) used to prevent and treat blood clots. It is marketed by Bayer AG and is available in various forms, including tablets and oral solutions. Ryvyco works by inhibiting the action of factor Xa, a key enzyme in the blood clotting process.

The primary indication for Ryvyco is the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF). It is also used for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients who are at high risk for bleeding. Ryvyco is typically administered once daily, with or without food, and the dosage is adjusted based on the patient's specific condition and response to treatment.

Ryvyco is generally well-tolerated, but like all medications, it can cause side effects. Common side effects include nausea, diarrhea, and abdominal pain. Serious side effects may include bleeding, which can be life-threatening. Therefore, it is important for patients to follow their healthcare provider's instructions and report any unusual symptoms or side effects.

Ryvyco is not recommended for patients with a history of bleeding disorders or those who are at high risk for bleeding. It is also contraindicated in patients with mechanical heart valves or those who have undergone recent major surgery. As with any medication, the use of Ryvyco should be carefully considered and monitored by a healthcare professional.